诚达药业：股东前海晟泰累计减持公司股份约291万股，本次减持计划期限届满

Group 1 - The core point of the article is that Chengda Pharmaceutical has received a notice regarding the progress of a share reduction plan by Qianhai Shengtai, which has reduced its holdings by approximately 2.91 million shares, accounting for 1.92% of the total share capital after excluding repurchased shares [1] - As of the end of 2024, Chengda Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 55.67%, food manufacturing accounts for 43.0%, other businesses account for 0.69%, and trading revenue accounts for 0.65% [1] - The current market capitalization of Chengda Pharmaceutical is 6.6 billion yuan [1]